Quoin Wins FDA Fast Track for QRX003 in Netherton

Quoin Pharmaceuticals ( (QNRX) ) has provided an announcement.

On March 11, 2026, Quoin Pharmaceuticals announced that the U.S. Food and Drug Administration granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare, inherited skin disorder with no approved therapies. QRX003 is already in two late-stage whole-body clinical trials and has previously received Orphan Drug and Pediatric Rare Disease designations in the U.S., as well as Orphan Drug status from the European Medicines Agency.

Fast Track status is intended to facilitate development and speed regulatory review of drugs addressing serious conditions with unmet medical need, giving QRX003 access to more frequent FDA interactions and potential eligibility for rolling review and accelerated approval pathways. The move further strengthens Quoin’s positioning in the rare dermatology space and underscores the potential for QRX003 to become the first approved treatment for Netherton Syndrome, a milestone that could be material for both patients and the company’s rare-disease portfolio.

The most recent analyst rating on (QNRX) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.

Spark’s Take on QNRX Stock

According to Spark, TipRanks’ AI Analyst, QNRX is a Neutral.

The score is held down primarily by weak financials (no revenue, sizable losses, and significant cash burn with negative equity), reinforced by bearish technical signals (below key moving averages with negative MACD). Positive corporate catalysts (orphan designation and breakthrough application) provide some offset, but do not outweigh the current funding and execution risks.

To see Spark’s full report on QNRX stock, click here.

More about Quoin Pharmaceuticals

Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases. The company’s pipeline includes candidates targeting Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and other underserved indications.

Quoin is committed to addressing significant unmet medical needs for patients, their families, and care teams in niche dermatological and vascular conditions. Its strategy centers on advancing innovative therapies through late-stage clinical development in order to secure approvals in markets where there are currently limited or no approved treatment options.

Average Trading Volume: 33,682

Technical Sentiment Signal: Strong Sell

Current Market Cap: $5.05M

For a thorough assessment of QNRX stock, go to TipRanks’ Stock Analysis page.